Literature DB >> 15761774

Costs of hospitalization for severe acute asthma of patients not treated according to guidelines and recommendations. French prospective study of 169 cases.

Jean-Claude Sailly1, Xavier Lenne, Caroline Bercez, Thérèse Lebrun, Antoine-Bernard Tonnel, Isabelle Tillie-Leblond.   

Abstract

This prospective study of 169 adult patients hospitalized for severe acute asthma in four pneumology wards compared the incidence and costs of patients who were managed (group A) or not managed (group P) before hospitalization, according to the guidelines and international recommendations (11 criteria judged by experts). Ambulatory costs were calculated by questioning patients. Valuation of hospital costs was based DRGs weighted by length of stay. The incidence in group P patients was estimated at 70%; A patients were 14 years younger than those in group P and had less severe asthma. Their annual ambulatory care prior to hospitalization was less costly irrespective of age category or degree of severity (euro 685 vs. euro 1,145 in group A); their length of hospital stay was shorter (6.03 vs. 10.78 days), resulting in a lower cost of hospitalization (euro 2,820 vs. euro 4,843). In group P a specific education program based on increased understanding, compliance, self-management, and smoking cessation, particularly in young patients should lead to reductions in hospitalizations.

Entities:  

Mesh:

Year:  2005        PMID: 15761774     DOI: 10.1007/s10198-005-0277-2

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  2 in total

1.  Cardiac output assessed by non-invasive monitoring is associated with ECG changes in children with critical asthma.

Authors:  Jackson Wong; Kate Dorney; Megan Hannon; Garry M Steil
Journal:  J Clin Monit Comput       Date:  2013-07-20       Impact factor: 2.502

Review 2.  Economic burden of asthma: a systematic review.

Authors:  Katayoun Bahadori; Mary M Doyle-Waters; Carlo Marra; Larry Lynd; Kadria Alasaly; John Swiston; J Mark FitzGerald
Journal:  BMC Pulm Med       Date:  2009-05-19       Impact factor: 3.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.